Table 5.
AE, n (%) | Phase 1 dose escalation (all doses) (N=31) |
Phase 2- Filanesib (N=32) |
Phase 2- Filanesib/Dex (N=55) |
---|---|---|---|
Death | 0 (0) | 1 (3) | 1 (2) |
Fatigue | 0 (0) | 2 (6) | 0 (0) |
Arthritis bacterial | 0 (0) | 0 (0) | 1 (2) |
Pneumonia | 0 (0) | 0 (0) | 1 (2) |
Sepsis | 1 (3) | 0 (0) | 1 (2) |
Septic shock | 0 (0) | 0 (0) | 1 (2) |
Thrombocytopenia | 1 (3) | 0 (0) | 2 (4) |
Febrile neutropenia | 0 (0) | 0 (0) | 1 (2) |
Hypercalcemia | 0 (0) | 0 (0) | 2 (4) |
Dehydration | 0 (0) | 0 (0) | 1 (2) |
Fluid overload | 0 (0) | 1 (3) | 0 (0) |
Acute respiratory distress syndrome | 0 (0) | 0 (0) | 1 (2) |
Dyspnea | 0 (0) | 0 (0) | 1 (2) |
Cardiac failure congestive | 0 (0) | 0 (0) | 1 (2) |
Renal failure acute | 0 (0) | 0 (0) | 1 (2) |
Blister | 0 (0) | 1 (3) | 0 (0) |
Leukopenia | 1 (3) | 0 (0) | 0 (0) |
Neutropenia | 1 (3) | 0 (0) | 0 (0) |
Atrial fibrillation | 1 (3) | 0 (0) | 0 (0) |
Vision blurred | 1 (3) | 0 (0) | 0 (0) |
This table is based on the safety population.
Abbreviations: AE = adverse event(s); Dex = dexamethasone; N or n = number